Acadia Pharmaceuticals: Why I'm Bullish Ahead Of The RADIANT Readout
We bridge the gap between financial information and actionable insight by providing unrivaled coverage on all asset classes and access to best-in-class tools. Invest.","telephone":"+1-347-509-6837","url":"https://seekingalpha.com"},"datePublished":"2026-07-27T13:27:25.000Z","dateModified":"2026-07-27T13:28:44.000Z","description":"Acadia Pharmaceuticals Inc. outlook: RADIANT Phase 2 remlifanserin data due Aug–Oct 2026, 2026 revenue guidance $1.22–$1.28B and 32% upside. Richard Drury/DigitalVision via Getty Images Acadia Pharmaceuticals Inc. (ACAD) is one of my favorites in the neurodegenerative disease treatment market.
- ▪We bridge the gap between financial information and actionable insight by providing unrivaled coverage on all asset classes and access to best-in-class tools.
- ▪Invest.","telephone":"+1-347-509-6837","url":"https://seekingalpha.com"},"datePublished":"2026-07-27T13:27:25.000Z","dateModified":"2026-07-27T13:28:44.000Z","description":"Acadia Pharmaceuticals Inc. outlook: RADIANT Phase 2 remlifanserin
- ▪Richard Drury/DigitalVision via Getty Images Acadia Pharmaceuticals Inc. (ACAD) is one of my favorites in the neurodegenerative disease treatment market.
Seeking Alpha files mainly under finance. We currently carry 6,685 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | Seeking Alpha |
| Canonical URL | https://seekingalpha.com/article/4925854-acadia-pharmaceuticals-why-im-bullish-ahead-of-the-radiant-readout?source=feed_all_articles |
| Publication time | Mon, 27 Jul 2026 09:27:25 -0400 |
| Retrieval time | 2026-07-27T13:31:21.621Z |
| Last seen | 2026-07-27T13:31:21.621Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | Li76bjUmQKxe · 1 stories |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://seekingalpha.com/"},{"@type":"ListItem","position":2,"name":"Earnings Analysis","item":"https://seekingalpha.com/earnings/earnings-analysis"},{"@type":"ListItem","position":3,"name":"Healthcare ","item":"https://seekingalpha.com/stock-ideas/healthcare"}]}{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4925854-acadia-pharmaceuticals-why-im-bullish-ahead-of-the-radiant-readout"},"author":{"@type":"Person","name":"ALLKA…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
